Regeneron Could Have a Big Catalyst Coming in 2022

Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) announced last month that the U.S. Food and Drug Administration (FDA) had accepted their jointly developed cancer drug, Libtayo, for priority review as a treatment for patients with recurrent or metastatic cervical cancer whose disease continued to worsen during or after chemotherapy treatment. The agency is planning to deliver its decision on Libtayo's fourth cancer indication by Jan. 30.  

So let's take a look at how effective Libtayo appears to be in treating cervical cancer, and how much of a boost that FDA approval could give to Regeneron.

Image source: Getty Images.

Continue reading

Source Fool.com